|
|
|
|
|
|
Sponsors and Collaborators: |
Abbott Genentech |
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00517790 |
The primary objectives of this study are to determine the efficacy of two different doses of ABT-869 using Response Evaluation Criteria in Solid Tumors (RECIST) and to establish the safety/tolerability profile of ABT-869 in subjects with advanced or metastatic NSCLC who have had at least one but no more than two prior lines of systemic treatment.
The secondary objectives of this study are to identify potential biomarkers that correlate and/or predict efficacy and toxicity in subjects with advanced or metastatic NSCLC and to explore if there are any ethnic differences in tumor response to ABT-869 between Asian and non-Asian NSCLC populations.
Condition | Intervention | Phase |
Non-Small Cell Lung Cancer (NSCLC) |
Drug: ABT-869 |
Phase II |
MedlinePlus related topics: | Cancer Lung Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Estimated Enrollment: | 120 |
Study Start Date: | August 2007 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
0.25 mg/kg: Experimental
High dose
|
Drug: ABT-869
0.25 mg/kg or 0.10 mg/kg
|
0.10 mg/kg: Experimental
Low Dose
|
Drug: ABT-869
0.25 mg/kg or 0.10 mg/kg
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Karen E Burns | Karen.Burns@abbott.com | |
Contact: Christa A. Lee, BS | christa.lee@abbott.com |
Show 38 Study Locations |
Abbott |
Genentech |
Study Director: | Joyce Steinberg, MD | Abbott |
Responsible Party: | Abbott ( Rod Humerickhouse, MD, Global Project Head ) |
Study ID Numbers: | M06-880 |
First Received: | August 16, 2007 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00517790 |
Health Authority: | United States: Food and Drug Administration; Singapore: Health Sciences Authority |
|
|
|